Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Nat Biomed Eng. 2022 Jan 31;6(3):232–245. doi: 10.1038/s41551-021-00837-3

Fig. 1 |. cfDNA tests in clinical diagnostics for NSCLC, and treatment workflow.

Fig. 1 |

cfDNA screening can be used in combination with a physical exam, a chest X-ray and a CT scan. Approximately 70% of patients with NSCLC are diagnosed at a late stage (stages III or IV) following overt clinical symptoms. The most common use of cfDNA analysis is in therapy selection for patients at stages IIIb or IV. The technologies of cfDNA analysis can be used for post-treatment monitoring, including the detection of recurrence and de novo resistance mutations. TKI, tyrosine kinase inhibitor.